Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-11-19

Clinical Trial Update: Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2) [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study of GLPG0634 as monotherapy in active rheumatoid arthritis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GLPG0634 (filgotinib)

Snippet

Sponsor: Galapagos NV | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2020-11-19